Varkarakis John, Pinggera Germar-Michael, Sebe Philippe, Berger Andreas, Bartsch Georg, Horninger Wolfgang
Department of Urology, Innsbruck University, Innsbruck, Austria.
Urology. 2004 Feb;63(2):337-41. doi: 10.1016/j.urology.2003.09.032.
To evaluate the incidence and outcome of prostate cancer in men younger than 45 years of age treated with radical retropubic prostatectomy after screening in an early prostate cancer detection program.
Our study group comprised 19,302 men younger than 45 years old who participated in this program. The indications for prostate biopsy were a prostate-specific antigen (PSA) level of 1.25 ng/mL or greater and a percent-free PSA value of 18% or less. Patients with prostate cancer underwent nerve-sparing radical retropubic prostatectomy. Intraoperative and early postoperative complications, clinical and pathologic stage, Gleason score, and surgical margins were reviewed retrospectively. In addition, potency, continence, and biochemical recurrence were assessed at the last follow-up visit.
Of the study population eligible for prostate biopsy (1027 patients), only 175 (17%) consented to undergo the procedure (mean PSA 3.8 ng/mL). Twenty-eight men were diagnosed with prostate cancer, corresponding to 0.14% of the screened population and 16% of the biopsied patients. Twenty-six patients agreed to undergo radical retropubic prostatectomy. Pathologic examination revealed organ-confined disease in 22 (84.6%) and extraprostatic extension in 4 (15.4%). Positive surgical margins were seen in 2 patients (7.7%). The Gleason score was 7 or greater in 11 (42.3%) and 6 or less in 15 patients (57.7%). During a mean follow-up period of 15.8 months (range 3 to 36), all patients were continent, and 13 of the 16 patients with a follow-up of 12 months or longer were potent.
In a large screening population younger than 45 years old, 16% of biopsied patients were positive for prostate cancer. These tumors were clinically significant but of a low stage and therefore potentially curable by surgery.
评估在早期前列腺癌检测项目筛查后接受耻骨后根治性前列腺切除术治疗的45岁以下男性前列腺癌的发病率及治疗结果。
我们的研究组包括19302名参与该项目的45岁以下男性。前列腺活检的指征为前列腺特异性抗原(PSA)水平为1.25 ng/mL或更高且游离PSA值为18%或更低。前列腺癌患者接受保留神经的耻骨后根治性前列腺切除术。回顾性分析术中及术后早期并发症、临床及病理分期、Gleason评分和手术切缘情况。此外,在最后一次随访时评估性功能、控尿能力及生化复发情况。
在符合前列腺活检条件的研究人群(1027例患者)中,仅有175例(17%)同意接受该检查(平均PSA 3.8 ng/mL)。28名男性被诊断为前列腺癌,占筛查人群的0.14%,活检患者的16%。26例患者同意接受耻骨后根治性前列腺切除术。病理检查显示22例(84.6%)为器官局限性疾病,4例(15.4%)有前列腺外侵犯。2例患者(7.7%)手术切缘阳性。Gleason评分7分及以上者11例(42.3%),6分及以下者15例(57.7%)。在平均15.8个月(范围3至36个月)的随访期内,所有患者均能控尿,在随访12个月或更长时间的16例患者中,13例性功能正常。
在一个大型的45岁以下筛查人群中,16%的活检患者前列腺癌呈阳性。这些肿瘤具有临床意义,但分期较低,因此有可能通过手术治愈。